Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children
| Autor: | Thomas G. Cleary, Iris Pecho, Dejian Lai, Miguel Campos, Theresa J. Ochoa, Angela Lluque, Nelly Baiocchi, Ana Prada, Elsa Chea-Woo, Gladys Valdiviezo |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Placebo-controlled study medicine.disease_cause Placebo Gastroenterology Article law.invention fluids and secretions Randomized controlled trial Double-Blind Method law Internal medicine medicine Animals Humans Shigella purl.org/pe-repo/ocde/ford#3.02.03 [https] biology Lactoferrin business.industry Campylobacter Incidence (epidemiology) food and beverages Infant Lactoferrin therapeutic use Surgery Diarrhea stomatognathic diseases Pediatrics Perinatology and Child Health Diarrhea Infantile biology.protein Cattle Female medicine.symptom Diarrhea Infantile business |
| Zdroj: | The Journal of pediatrics. 162(2) |
| ISSN: | 1097-6833 |
| Popis: | Objective To determine the effect of bovine lactoferrin (bLF) on prevention of diarrhea in children. Study design We conducted a community-based randomized double-blind placebo controlled trial comparing supplementation with bLF vs placebo. Previously weaned children were enrolled at 12-18 months and followed for 6 months with daily home visits for data collection and supplement administration. Anthropometric measures were done monthly. Results Five hundred fifty-five children were randomized: 277 to bLF and 278 to placebo; 65 dropped out; 147 894 doses were administered (92% compliance). Overall there were 91 446 child-days of observation and 1235 diarrhea episodes lasting 6219 days. The main pathogens isolated during diarrheal episodes were norovirus (35.0%), enteropathogenic E coli (11.4%), Campylobacter (10.6%), enteroaggregative E coli (8.4%), enterotoxigenic E coli (6.9%), and Shigella (6.6%). The diarrhea incidence was not different between groups: 5.4 vs 5.2 episodes/child/year for bLF and placebo, respectively ( P = .375). However, the diarrhea longitudinal prevalence was lower in the bLF group vs placebo (6.6% vs 7.0%, P = .017), as well as the median duration of episodes (4.8 vs 5.3 days, P = .046), proportion of episodes with moderate or severe dehydration (1.0% vs 2.6%, P = .045), and liquid stools load (95.0 vs 98.6) liquid stools/child/year, P Conclusions Although there was no decrease in diarrhea incidence, longitudinal prevalence and severity were decreased with LF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect